DDRE-18. DEVELOPMENT OF EGFRvIII AND EGFR DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME

BACKGROUND: Chimeric antigen receptor T cell (CART) therapy has revolutionized the treatment landscape for hematological malignancies, its efficacy remains limited in solid tumors. EGFRvIII is a truncated version of the wild type EGFR in which deletion of exons 2–7 of the extracellular domain leads...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Ruff, Michael, Sakemura, Reona, Manriquez-Roman, Claudia, Hefazi-Torghabeh, Mehrdad, Schick, Kendall, Michelle, Cox, Can, Ismail, Horvei, Paulina, Siegler, Elizabeth, Tapper, Erin, Kenderian, Saad
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Drug Discovery, Drug Resistance
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651519/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.263
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars